Mosaic ImmunoEngineering, Inc. reported a net loss of $172,028 for the three months ended June 30, 2025, a decrease from a net loss of $293,717 in the same period of the previous year. For the six months ended June 30, 2025, the company recorded a net loss of $353,348, down from $582,209 in the prior year. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $148,854 for the second quarter of 2025, compared to $274,302 in the same quarter of 2024. The company’s cash and cash equivalents decreased to $53,583 as of June 30, 2025, from $115,019 at the end of 2024.
The company has made notable strategic adjustments, including a focus on reducing operating expenses. Research and development expenses fell to $16,006 in the second quarter of 2025 from $60,707 in the same quarter of 2024, primarily due to reduced payroll costs. General and administrative expenses also decreased to $132,848 from $213,595 year-over-year, reflecting a similar trend in cost management. The company has not generated any revenue to date, which continues to impact its financial position.
Mosaic ImmunoEngineering is actively pursuing strategic partnerships to enhance its product pipeline. In April 2024, the company entered into a Binding Term Sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain cancer therapies and AI technologies. This agreement is contingent upon the completion of due diligence and shareholder approval, with a definitive agreement expected to be negotiated. However, the Binding Term Sheet expired on June 30, 2025, indicating a need for timely execution to secure these potential advancements.
Operationally, the company has not reported any significant changes in customer counts or user statistics, as it remains in the development stage. The employee headcount has not been disclosed, but the company has indicated a need for additional personnel to support future growth. The company’s ability to continue operations is highly dependent on its capacity to raise capital, as it anticipates that current cash reserves will not meet operational needs for the next twelve months. The filing highlights ongoing uncertainties related to market conditions, including inflation and potential economic downturns, which may hinder fundraising efforts.
Looking ahead, Mosaic ImmunoEngineering emphasizes the importance of securing additional financing to support its research and development initiatives. The company has no current arrangements for additional capital and acknowledges the challenges posed by current market conditions. If it fails to raise sufficient funds, there is a risk of ceasing operations altogether, raising substantial doubt about its ability to continue as a going concern.
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering is a biotechnology company focused on developing immunotherapies for cancer treatment. It aims to identify, license, and acquire innovative product candidates and platforms, leveraging expertise in immuno-oncology. The company explores novel therapies, including AI-driven combination strategies, with a pipeline primarily in early-stage preclinical development, targeting unmet medical needs in oncology markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.